📣 VC round data is live. Check it out!

Sartorius Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sartorius and similar public comparables like Divi's Laboratories, Wuxi Biologics, Steris, Illumina and more.

Sartorius Overview

About Sartorius

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.


Founded

1978

HQ

United States

Employees

10.3K

Financials (LTM)

Revenue: $4B
EBITDA: $1B

EV

$21B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sartorius Financials

Sartorius reported last 12-month revenue of $4B and EBITDA of $1B.

In the same LTM period, Sartorius generated $2B in gross profit, $1B in EBITDA, and $378M in net income.

Revenue (LTM)


Sartorius P&L

In the most recent fiscal year, Sartorius reported revenue of $4B and EBITDA of $1B.

Sartorius is profitable as of last fiscal year, with gross margin of 45%, EBITDA margin of 31%, and net margin of 9%.

See analyst estimates for Sartorius
LTMLast FY202320242025202620272028
Revenue$4B$4B$3B$3B$3B
Gross Profit$2B$2B$1B$1B$2B
Gross Margin46%45%44%43%45%
EBITDA$1B$1B$885M$786M$973M
EBITDA Margin31%31%27%24%28%
EBIT Margin21%21%17%14%18%
Net Profit$378M$314M$363M$205M$311M
Net Margin11%9%11%6%9%
Net Debt—$2B———

Financial data powered by Morningstar, Inc.

Sartorius Stock Performance

Sartorius has current market cap of $19B, and enterprise value of $21B.

Market Cap Evolution


Sartorius' stock price is $195.89.

Sartorius share price increased by 7.0% in the last 30 days, and decreased by 12.5% in the last year.

Sartorius has an EPS (earnings per share) of $3.23.

See more trading valuation data for Sartorius
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$21B$19B3.2%7.0%-9.4%-12.5%$3.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sartorius Valuation Multiples

Sartorius trades at 6.0x EV/Revenue multiple, and 19.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Sartorius

EV / Revenue (LTM)


Sartorius Financial Valuation Multiples

As of May 8, 2026, Sartorius has market cap of $19B and EV of $21B.

Sartorius has a P/E ratio of 50.5x.

LTMLast FY202320242025202620272028
EV/Revenue6.0x6.1x6.6x6.6x6.2x
EV/EBITDA19.4x19.9x24.3x27.3x22.1x
EV/EBIT28.2x29.7x39.0x46.1x34.0x
EV/Gross Profit12.9x13.6x14.9x15.2x13.6x
P/E50.5x60.7x52.5x92.9x61.2x
EV/FCF61.0x61.3x67.2x38.6x61.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sartorius Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sartorius Margins & Growth Rates

Sartorius grew revenue by 6% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, Sartorius reported gross margin of 45%, EBITDA margin of 31%, and net margin of 9%.

See estimated margins and future growth rates for Sartorius

Sartorius Margins

Last FY202420252026202720282029
Gross Margin45%43%45%47%
EBITDA Margin31%24%28%31%
EBIT Margin21%14%18%22%
Net Margin9%6%9%13%
FCF Margin10%17%10%11%

Sartorius Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%0%7%7%
Gross Profit Growth11%(2%)11%11%
EBITDA Growth7%(11%)24%19%
EBIT Growth15%(15%)36%32%
Net Profit Growth58%(43%)52%60%
FCF Growth21%74%(37%)21%

Data powered by FactSet, Inc. and Morningstar, Inc.

Sartorius Operational KPIs

Sartorius' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Sartorius' Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sartorius' Rule of X is 49% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sartorius
LTMLast FY202320242025202620272028
Rule of 4039%38%———
Bessemer Rule of X51%49%———
Revenue per Employee—$0.3M———
Opex per Employee—$0.1M———
S&M Expenses to Revenue16%16%16%17%16%
G&A Expenses to Revenue6%6%6%6%6%
R&D Expenses to Revenue4%4%5%5%4%
Opex to Revenue—27%27%29%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sartorius Competitors

Sartorius competitors include Divi's Laboratories, Wuxi Biologics, Steris, Illumina, Labcorp, Quest Diagnostics, Hologic, Zimmer Biomet, DexCom and Halma.

Most Sartorius public comparables operate across Medical Devices, Laboratory Services, Contract Research & Manufacturing, DeepTech, HealthTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Divi's Laboratories16.8x16.1x52.6x48.8x
Wuxi Biologics4.9x4.6x12.0x11.9x
Steris4.1x3.8x14.2x13.5x
Illumina5.2x5.1x15.4x18.0x
Labcorp2.0x1.9x11.4x11.2x
Quest Diagnostics2.5x2.4x12.5x12.2x
Hologic————
Zimmer Biomet2.8x2.8x8.3x8.3x

This data is available for Pro users. Sign up to see all Sartorius competitors and their valuation data.

Start Free Trial

Sartorius M&A Activity

Sartorius has acquired 16 companies to date.

Last acquisition by Sartorius was on July 1st 2025. Sartorius acquired MatTek for $80M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Sartorius

MatTek
Polyplus-transfection
Albumedix
ALS Automated Lab Solutions
Description
—
Polyplus-transfection is an Illkirch-based biotechnology firm near Strasbourg developing transfection reagents for nucleic acid delivery in research, bioproduction, and therapeutics. Its portfolio includes jetPEI, jetPRIME, and in vivo-jet for DNA, siRNA, and mRNA transfection. ISO 9001-certified since 2002, the company supplies over 5,000 labs worldwide and supports clinical trials for gene therapies.
Albumedix is a Nottingham-headquartered biotechnology firm that engineers albumin fusion technologies for biopharmaceuticals. Its platform enhances drug half-life, stability, and bioavailability in treatments for cancer, diabetes, and rare diseases. Partners including Sanofi and Novo Nordisk incorporate Albumedix albumin variants in approved therapies like Levemir insulin. The company operates GMP facilities in Denmark and the UK for clinical supply.
ALS Automated Lab Solutions develops the CellCelector system, a Jena, Germany-based automated platform for fluorescence imaging and single-cell picking in mammalian cell line development. It handles semi-solid media with disposable tips and real-time quality control for biotech applications worldwide.
HQ CountryUnited StatesFranceUnited KingdomGermany
HQ City
—
Strasbourg
Nottingham
Erfurt
Deal Date1 Jul 20255 Apr 20238 Aug 202216 Dec 2021
Valuation$80M$3B$471M$41M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sartorius acquisitions and their M&A valuation multiples.

Start Free Trial

Sartorius Investment Activity

Sartorius has invested in 2 companies to date.

Latest investment by Sartorius was on August 11th 2025. Sartorius invested in Nanotein Technologies in their $3M Strategic investment round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Sartorius

Nanotein Technologies
SPARTA Biodiscovery
Description
Nanotein Technologies is a South Korean biotechnology company designing protein therapeutics for cancer immunotherapy. Its engineered minibodies target immune checkpoints with high specificity and long half-lives. Daejeon-headquartered, Nanotein advances candidates into preclinical studies for solid tumors.
SPARTA Biodiscovery is a Barcelona-based biotechnology company specializing in nanoformulations to enhance drug delivery for emerging therapies. Platforms optimize solubility, bioavailability, and targeted release for oncology and rare disease candidates. Collaborations with pharmaceutical partners advance lipid nanoparticles and polymeric carriers through preclinical development stages.
HQ CountryUnited StatesUnited Kingdom
HQ City
San Francisco, CA
London
Deal Date11 Aug 202528 Sep 2023
RoundStrategic investmentSeed
Raised$3M$4M
InvestorsSartoriusSartorius
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sartorius investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sartorius

When was Sartorius founded?Sartorius was founded in 1978.
Where is Sartorius headquartered?Sartorius is headquartered in United States.
How many employees does Sartorius have?As of today, Sartorius has over 10K employees.
Who is the CEO of Sartorius?Sartorius' CEO is Rene Faber.
Is Sartorius publicly listed?Yes, Sartorius is a public company listed on Euronext Paris.
What is the stock symbol of Sartorius?Sartorius trades under DIM ticker.
When did Sartorius go public?Sartorius went public in 1994.
Who are competitors of Sartorius?Sartorius main competitors include Divi's Laboratories, Wuxi Biologics, Steris, Illumina, Labcorp, Quest Diagnostics, Hologic, Zimmer Biomet, DexCom, Halma.
What is the current market cap of Sartorius?Sartorius' current market cap is $19B.
What is the current revenue of Sartorius?Sartorius' last 12 months revenue is $4B.
What is the current revenue growth of Sartorius?Sartorius revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Sartorius?Current revenue multiple of Sartorius is 6.0x.
Is Sartorius profitable?Yes, Sartorius is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Sartorius?Sartorius' last 12 months EBITDA is $1B.
What is Sartorius' EBITDA margin?Sartorius' last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Sartorius?Current EBITDA multiple of Sartorius is 19.4x.
What is the current FCF of Sartorius?Sartorius' last 12 months FCF is $352M.
What is Sartorius' FCF margin?Sartorius' last 12 months FCF margin is 10%.
What is the current EV/FCF multiple of Sartorius?Current FCF multiple of Sartorius is 61.0x.
How many companies Sartorius has acquired to date?As of May 2026, Sartorius has acquired 16 companies.
What was the largest acquisition by Sartorius?$3B acquisition of Polyplus-transfection on 5th April 2023 was the largest M&A Sartorius has done to date.
What companies Sartorius acquired?Sartorius acquired Polyplus-transfection, Danaher Life Science, ForteBio, Albumedix, Essen BioScience, CellGenix, Biological Industries Ltd, Intellicyt, MatTek, MKS Umetrics, and 6 other companies.
In how many companies Sartorius has invested to date?As of May 2026, Sartorius has invested in 2 companies.
What was the last Sartorius investment?On 11th August 2025 Sartorius invested in Nanotein Technologies, participating in a $3M Strategic investment round.
In what companies Sartorius invested in?Sartorius invested in SPARTA Biodiscovery and Nanotein Technologies.

See public comps similar to Sartorius

Lists including Sartorius

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial